Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 8/20 | 0.43 |
| ▸ | HTR1A | P08908 | 5/20 | 0.43 |
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | HTR7 | P34969 | 5/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2598572 | 0.88 | HTR2A (0.44) | HTR2AMTNR1AMTNR1BHTR6HTR1A | |
| SCHEMBL16494290 | 0.87 | HTR2A (0.43) | HTR2AMTNR1AMTNR1BHTR6HTR1A | |
| SCHEMBL14840253 | 0.83 | HTR2A (0.50) | HTR2AMTNR1AMTNR1B | |
| SCHEMBL2598664 | 0.83 | IP6K1 (0.47) | HTR2AMTNR1AMTNR1BHTR6 | |
| SCHEMBL16495155 | 0.82 | HTR2A (0.39) | HTR2AHTR1ADHFRHTT | |
| SCHEMBL16494641 | 0.82 | MTNR1A (0.43) | HTR2AMTNR1AMTNR1BHTR6HTR1A | |
| SCHEMBL16494650 | 0.81 | HTR1A (0.39) | HTR2AHTR6HTR1ADRD2HTR7 | |
| SCHEMBL12185425 | 0.81 | MTNR1A (0.43) | HTR2AMTNR1AMTNR1BHTR6HTR1A | |
| SCHEMBL14839993 | 0.80 | HTR2A (0.42) | HTR2AMTNR1AMTNR1BHTR6HTR1A | |
| SCHEMBL14839726 | 0.80 | MPO (0.47) | HTR2AMTNR1AMTNR1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571867-B1 | NOVEL PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2015-11-04 | — | — | EP | claimed |
| US-8927547-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-01-06 | — | — | US | claimed |
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2013-04-11 | — | — | US | claimed |
| EP-2571867-A1 | NOVEL PYRIMIDINE DERIVATIVES | Chemilia AB (SE) | 2013-03-27 | — | — | EP | claimed |
| WO-2011144742-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2011-11-24 | — | — | WO | claimed |
| EP-2571867-B1 | NOVEL PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| US-8927547-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-01-06 | — | — | US | disclosed |
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2013-04-11 | — | — | US | disclosed |
| EP-2395001-A1 | Novel pyrimidine derivatives | Chemilia AB (SE) | 2011-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | HTR2A 2961/4885MTNR1A 3619/4885MTNR1B 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.